TY - JOUR T1 - ADIPOSE-DERIVED STROMAL VASCULAR FRACTION AND FAT GRAFTS VERSUS MEDICAL TREATMENT FOR TREATING THE HANDS OF PATIENTS WITH SYSTEMIC SCLEROSIS. A RANDOMIZED CRONTOLLED TRIAL JF - medRxiv DO - 10.1101/2021.02.08.21250465 SP - 2021.02.08.21250465 AU - Martin Iglesias AU - Iván Torre-Villalvazo AU - Patricia Butrón-Gandarillas AU - Tatiana S. Rodríguez-Reyna AU - Erik A. Torre-Anaya AU - Armando R. Tovar-Palacio AU - Alejandro Zentella-Dehesa AU - Martha Guevara-Cruz AU - Alan M Hérnandez-Campos Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/02/11/2021.02.08.21250465.abstract N2 - Background In the hand, the Systemic Sclerosis (SS) is characteristically evidenced by Raynaud’s phenomenon (RP) and fibrosis of the skin, tendons, ligaments, and joints as well as digital ulcers with prolonged healing. Current medical treatment not always cure these complications. Local adipose-derived stromal vascular fraction (ADSVF) administration into the hands has been proposed as an emerging treatment for these complications, due to its proangiogenic, antifibrotic, and immunoregulatory activities. The objective of this controlled trial was to evaluate the safety and clinical effects of fat micrografts plus ADSVF administration into the hands of patients with SS.Methods This was an open-label, monocentric, randomized controlled study. Twenty patients diagnosed with SS were enrolled and assigned to the experimental or control group. Fat micrografts plus the ADSVF were injected into the right hand of experimental group patients. The control group continued to receive only medical treatment. Demographic, serologic data and disease severity were recorded. Digital oximetry, pain, Raynaud phenomenon (RP), digital ulcer healing (DUH), mobility, thumb opposition, vascular density of the nail bed, skin affection of the hand, Serologic antibodies, hand function, and quality of life scores were evaluated in both groups. The mean follow-up period was 168 days.The differences between before and after the intervention were analyzed with the Wilcoxon range test, and the differences between the control and experimental groups at 0 days and 168 days were analyzed with the Mann–Whitney U test.Results Adverse events were not observed in both groups. There were no changes in disease severity, serologic antibodies, nailfold capillaroscopy patterns, mobility, and hand function in both groups. There were significant improvements in pain, DUH and quality of life scores in the experimental group. RP improved significantly in both groups. However, on statistically comparing the results at 168 days between the groups, significant improvements were only observed in pain levels (p = 0.02) and DUH (p=0.003).Conclusions The injection of ADSVF plus fat micrografts is a reproducible, and safe technique. Pain and digital ulcers in the hands of patients with SS can be treated with this treatment.Trial Registration Retrospectively registered in ClinicalTrials.gov with identifier NCT04387825Competing Interest StatementThe authors have declared no competing interest.Clinical TrialRegistered in ClinicalTrials.gov with identifier NCT04387825Funding StatementConsejo Nacional de Ciencia y Tecnologia (CONACYT) funding this research, with the Sectorial Research Fund in Health and Social Security I0000/739/2017.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:the Institutional Review Committee of the Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran has approved this protocol with the reference, SCI-1505-15/15-1. with date October, 6, 2017All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data generated or analyzed during this study are included in this published article and its supplementary information files as Additional File 1 Table A, Additional File 2 Table B, Additional file 3 Statistics, Additional File 4 Patient and Public Involvement 1, and Additional File 5 Patient and public involvement 2.SSSystemic SclerosisRPRaynaud phenomenonASCsAdipose stem cellsADSVFAdipose-Derived Stromal Vascular FractionDUHDigital Ulcer HealingPBSPhosphate-buffered saline ER -